AGIO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
55.4M
+23.8%
44.7M
+115.7%
20.7M
+3.9%
20.0M
+55.0%
12.9M
Cost of Revenue
2.5M
-15.7%
3.0M
+127.1%
1.3M
-29.8%
1.9M
+11.9%
1.7M
Gross Profit
52.9M
+26.6%
41.7M
+114.9%
19.4M
+7.4%
18.1M
+61.5%
11.2M
Operating Expenses
130.0M
-14.6%
152.3M
+17.7%
129.5M
-7.3%
139.7M
+9.1%
128.1M
R&D
73.5M
-27.1%
100.8M
+24.2%
81.1M
-7.8%
88.1M
+1.5%
86.8M
SG&A
56.5M
+9.7%
51.5M
+6.7%
48.3M
-6.4%
51.6M
+25.0%
41.3M
Operating Income
-77160000
+30.2%
-110552000
-0.5%
-110025000
+9.5%
-121578000
-4.0%
-116869000
EBITDA
-75708000
+30.7%
-109202000
-0.5%
-108662000
+9.7%
-120312000
-4.2%
-115495000
Net Income
-65045000
+35.4%
-100703000
-1.6%
-99111000
+8.3%
-108039000
-4.5%
-103433000
EPS (Basic)
$-1.09
+35.5%
$-1.69
+0.0%
$-1.69
+8.6%
$-1.85
-3.9%
$-1.78
EPS (Diluted)
$-1.09
+35.5%
$-1.69
+0.0%
$-1.69
+8.6%
$-1.85
-3.9%
$-1.78
Shares (Diluted)
59.7M
+0.4%
59.5M
+1.2%
58.8M
+0.7%
58.4M
+0.4%
58.1M
Agios Pharmaceuticals (AGIO) — Financials